

Appendix 1. Treatment with the farnesoid X receptor (FXR) agonist chenodeoxycholic acid (CDCA) promotes the expression of hepatitis B e antigen (HBeAg) in HepG2. HepG2 cells in 24-well plates were transfected with pHY106+wta and/or phFXR and treated with CDCA. HBeAg was measured with enzyme-linked immunosorbent assay (ELISA). * $P < 0.05$.



Appendix 2. Farnesoid X receptor (FXR) activation promotes the transcription from the hepatitis B virus (HBV) core promoter in HepG2. HepG2 cells were cotransfected with pGL3-EN2/CP and pRL-TK with or without phFXR. After treatment with chenodeoxycholic acid (CDCA) for 48 h, cells were harvested to detect firefly luciferase activity. * $P < 0.05$.



Appendix 3. Farnesoid X receptor (FXR) activation promotes the transcription of hepatitis B virus (HBV). HepG2 cells were transfected with pAAV/HBV1.2 with or without phFXR. After treatment with chenodeoxycholic acid (CDCA) for 48 h, cells were harvested for total RNA analysis. Reverse-transcription (RT)-PCR analysis of precore and pregenomic RNA (preC/pgRNA) transcription were performed. * $P < 0.05$.